20 years clinical use of GP IIb/IIIa receptor antagonists:What have we learned and where to go?Sep. 1, 2014
As an educational service we provide educational resources such as videopresentations of the actual lectures and presented slides to view and download (as PDF) to our PACE members
Prof J Wouter Jukema, Leiden, The Netherlands
Prof. Kurt Huber, Vienna, Austria
Prof. Jean-Philippe Collet, Paris, France
View & download presentation slides
Presentation by prof. J Wouter Jukema, MD, Leiden, The Netherlands
Presentation by prof. Kurt Huber, MD, Wilhelminen hospital, Vienna, Austria
Presentation by prof. Jean-Philippe Collet, MD, Department of Cardiology, Centre Hospitalier Universitaire Pitié-Salpêtrière , Paris, France
Educational objectives of the symposium
The goal of this program were to summarize the knowledge with regard to peri- and post procedural management of MI, based on patient cases.
After attending this program, the clinician will be better able to:
Understand the pathophysiology of acute MI with a focus on the mechanisms of platelet aggregation
Identify the role of GP IIb/IIIa inhibitors in ACS
Summarize the cumulative published clinical trial and registry data on the use of GP IIb/IIIa inhibitors in ACS patients undergoing PCI
Describe the outcomes of peri- and post procedural platelet inhibition in MI intervention
Discuss the selective use of GP IIb/IIIa inhibitors in international guidelines and in daily practice
Improve practical understanding of when and why to use GP IIb/IIIa inhibitors in ACS PCI patients
Discuss the future of antiplatelet therapies and their potential clinical implications
This programme was accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s). Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards the European Accreditation for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).
Supported by an unrestricted educational grant from Lilly.
In compliance with EBAC/ EACCME guidelines, all speakers/Chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee/ Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.”